Skip to main content
logo
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.09
+0.01 (0.21%)
Sep 2, 2026, 11:48 AM EDT - Market open

Entrada Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.6925.42210.78129.01--
Revenue Growth
-94.10%-87.94%63.38%---
Gross Profit
-134.36-115.1585.4829.13-66.61-35.93
Operating Income
-174.63-15647.01-3.16-97.25-51.13
Net Income
-165.78-143.7565.63-6.69-94.62-51.16
Earnings Per Share
-3.97-3.471.68-0.20-3.02-8.16
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
223.01295.7420351.97188.71291.06
Total Debt
48.5450.9359.2168.2325.94-
Net Cash (Debt)
174.46244.77360.79283.74162.78291.06
Net Cash Growth
-41.70%-32.16%27.16%74.31%-44.08%645.46%
Net Cash Per Share
4.185.929.258.595.2046.44

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-134.67-128.51-41.56139.8-93.79-50.86
Capital Expenditures
0.32-1.04-3.16-5.61-2.89-4.58
Free Cash Flow
-134.35-129.55-44.72134.19-96.67-55.44
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--40.55%22.58%--
Operating Margin
-3726.53%-613.66%22.30%-2.45%--
Pretax Margin
-3520.25%-561.84%31.54%9.34%--
Profit Margin
-3537.73%-565.48%31.14%-5.18%--
FCF Margin
-2867.07%-509.63%-21.21%104.01%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--9.33---
P/FCF Ratio
---3.75--
PS Ratio
54.4014.502.903.90--